Updates are available Correction dated 2019-05-17
Click to view Correction: https://doi.org/10.1038/s41588-019-0437-4
-
Authors
Hu, Xihao https://orcid.org/0000-0002-3517-6351
Zhang, Jian
Wang, Jin
Fu, Jingxin
Li, Taiwen
Zheng, Xiaoqi
Wang, Binbin
Gu, Shengqing
Jiang, Peng
Fan, Jingyu
Ying, Xiaomin
Zhang, Jing
Carroll, Michael C.
Wucherpfennig, Kai W.
Hacohen, Nir
Zhang, Fan
Zhang, Peng
Liu, Jun S. https://orcid.org/0000-0002-4450-7239
Li, Bo https://orcid.org/0000-0002-8617-900X
Liu, X. Shirley https://orcid.org/0000-0003-4736-7339
- License Information
-
More Information
Article History
Received: 8 September 2017
Accepted: 18 December 2018
First Online: 11 February 2019
Change Date: 17 May 2019
Change Type: Correction
Change Details: An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Competing interests
: X.S.L. is a cofounder and board member of GV20 Oncotherapy, SAB of 3DMed Care, consultant for Genentech, and stock holder of BMY, TMO, WBA, ABT, ABBV, and JNJ. J.S.L. is a cofounder and board member of Beijing Neoantigen Biotechnology Co. Ltd, and shareholder of BGNE, DVAX, CELG, NKTR, CRSP, and EDIT. K.W.W. serves on the SAB of Nextech, TCR2, and T-scan. He is also a consultant for Novartis. His laboratory has sponsored research agreements with Novartis, BMS, and Astellas. N.H. is a founder and SAB member of Neon Therapeutics and SAB member of IFM Therapeutics.
